UPDATE: Stifel Nicolaus Upgrades Healthways To Buy, Establishes $13 PT

Stifel Nicolaus raises its rating on Healthways, Inc. HWAY to Buy from Neutral and establishes a $13 target price as the company is seen well-positioned for a reformed world. Stifel says, “HWAY management has negotiated the prior three tumultuous years in healthcare fairly well. Revenue has declined but EBITDA margins have remained stable. The overall economy may be at an inflection point upward with recent employment trends improving. This should correlate positively for HWAY revenue.” HWAY closed at $6.49 per share on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorUpgradesPrice TargetPre-Market OutlookAnalyst RatingsStifel Nicolaus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!